Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study
- PMID: 31303316
- DOI: 10.1016/S0140-6736(19)31255-3
Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study
Abstract
Background: Differential diagnosis of diabetes insipidus is challenging. The most reliable approach is hypertonic saline-stimulated copeptin measurements. However, this test is based on the induction of hypernatraemia and requires close monitoring of plasma sodium concentrations. Arginine-stimulated copeptin measurements might provide an alternative, simple, and safe test.
Methods: In this prospective diagnostic study, we recruited a development cohort from University Hospital Basel, Basel, Switzerland, and a validation cohort from five centres in Basel, Aarau, Luzern, Bern, and St Gallen, Switzerland, and the University Hospital Würzburg, Würzburg, Germany. For both cohorts, patients were eligible for inclusion if they were aged 18 years or older, were newly referred with polyuria (>50 mL/kg bodyweight per day) or had a known diagnosis of central diabetes insipidus or primary polydipsia. We also recruited a comparator cohort of healthy controls in parallel to each cohort, comprising adults (aged 18 years and older, with normal drinking habits, and no history of polyuria) and children who underwent arginine stimulation to diagnose growth hormone deficiency (children were only included in the comparator cohort to the development cohort as proof of concept). Patients and healthy controls underwent arginine stimulation with measurement of plasma copeptin at baseline and 30, 45, 60, 90, and 120 min. The primary objective in the development cohort was to determine the diagnostic accuracy of plasma copeptin concentrations to discriminate between diabetes insipidus and primary polydipsia, and in the validation cohort was to confirm those results. Adverse effects of the test were monitored in all participants, with tolerability of the test rated using a visual analogue scale (VAS) that ranged from no (0) to maximum (10) discomfort. This trial is registered with ClinicalTrials.gov, number NCT00757276.
Findings: Between May 24, 2013, and Jan 11, 2017, 52 patients were enrolled in the development cohort (12 [23%] with complete diabetes insipidus, nine [17%] with partial diabetes insipidus, and 31 [60%] with primary polydipsia) alongside 20 healthy adults and 42 child controls. Between Oct 24, 2017, and June 27, 2018, 46 patients were enrolled in the validation cohort (12 [26%] with complete diabetes insipidus, seven [15%] with partial diabetes insipidus, and 27 [59%] with primary polydipsia) alongside 30 healthy adult controls (two patients in this cohort were excluded from the main analysis because of early vomiting during the test). In the pooled patient and control datasets, median arginine-stimulated copeptin concentrations increased in healthy adult controls (from 5·2 pM [IQR 3·3-10·9] to a maximum of 9·8 pM [6·4-19·6]) and in participants with primary polydipsia (from 3·6 pM [IQR 2·4-5·7] to a maximum of 7·9 pM [5·1-11·8]), but only minimally in those with diabetes insipidus (2·1 pM [IQR 1·9-2·7] to a maximum of 2·5 pM [1·9-3·1]). In the development cohort, a cutoff of 3·5 pM at 60 min provided the highest diagnostic accuracy of 94% (95% CI 84-98). The accuracy of this cutoff in the validation cohort was 86% (95% CI 73-94). By pooling the data from both cohorts, an optimal accuracy of 93% (95% CI 86-97) was reached at a cutoff of 3·8 pM copeptin at 60 min (sensitivity 93%, 95% CI 86-98; specificity 92%, 95% CI 84-100). The test was safe and well tolerated, with median VAS scores of 3·5 (IQR 2-4) in patients with diabetes insipidus, 3 (2-4) in those with primary polydipsia, 1 (1-3) in healthy adults, and 1 (0-5) in healthy children in the pooled participant dataset.
Interpretation: Arginine-stimulated copeptin measurements are an innovative test for diabetes insipidus with high diagnostic accuracy, and could be a simplified, novel, and safe diagnostic approach to diabetes insipidus in clinical practice.
Funding: Swiss National Science Foundation and University Hospital Basel.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
-
Testing the waters: a new test for hypotonic polyuria.Lancet. 2019 Aug 17;394(10198):546-547. doi: 10.1016/S0140-6736(19)31414-X. Epub 2019 Jul 11. Lancet. 2019. PMID: 31303317 No abstract available.
-
New test for diabetes insipidus.Nat Rev Endocrinol. 2019 Oct;15(10):564-565. doi: 10.1038/s41574-019-0247-x. Nat Rev Endocrinol. 2019. PMID: 31367010 No abstract available.
-
Use of copeptin in the diagnosis of polyuria-polydipsia syndrome.Lancet. 2020 Jan 25;395(10220):267. doi: 10.1016/S0140-6736(19)33000-4. Lancet. 2020. PMID: 31982061 No abstract available.
-
Changing the diagnostic approach to diabetes insipidus: role of copeptin.Ann Transl Med. 2019 Dec;7(Suppl 8):S285. doi: 10.21037/atm.2019.11.80. Ann Transl Med. 2019. PMID: 32016004 Free PMC article. No abstract available.
Similar articles
-
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies.Lancet Diabetes Endocrinol. 2025 Jun;13(6):505-515. doi: 10.1016/S2213-8587(25)00053-1. Epub 2025 Apr 25. Lancet Diabetes Endocrinol. 2025. PMID: 40294614 Clinical Trial.
-
Diagnostic Accuracy of Copeptin in the Differential Diagnosis of the Polyuria-polydipsia Syndrome: A Prospective Multicenter Study.J Clin Endocrinol Metab. 2015 Jun;100(6):2268-74. doi: 10.1210/jc.2014-4507. Epub 2015 Mar 13. J Clin Endocrinol Metab. 2015. PMID: 25768671
-
A post-hoc internal validation of arginine-stimulated copeptin cut-offs for diagnosing AVP deficiency (central diabetes insipidus).Pituitary. 2025 Apr 26;28(3):53. doi: 10.1007/s11102-025-01523-2. Pituitary. 2025. PMID: 40281371 Free PMC article.
-
Diagnostic Utility of Copeptin in Pediatric Patients with Polyuria-Polydipsia Syndrome: A Systematic Review and Meta-Analysis.Int J Mol Sci. 2024 Oct 5;25(19):10743. doi: 10.3390/ijms251910743. Int J Mol Sci. 2024. PMID: 39409072 Free PMC article.
-
Diagnosis and differential diagnosis of diabetes insipidus: Update.Best Pract Res Clin Endocrinol Metab. 2020 Sep;34(5):101398. doi: 10.1016/j.beem.2020.101398. Epub 2020 Feb 28. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 32387127 Review.
Cited by
-
Disorders of Salt and Water Balance After Pituitary Surgery.J Clin Endocrinol Metab. 2022 Dec 17;108(1):198-208. doi: 10.1210/clinem/dgac622. J Clin Endocrinol Metab. 2022. PMID: 36300330 Free PMC article.
-
Diagnosis and Management of Central Diabetes Insipidus in Adults.J Clin Endocrinol Metab. 2022 Sep 28;107(10):2701-2715. doi: 10.1210/clinem/dgac381. J Clin Endocrinol Metab. 2022. PMID: 35771962 Free PMC article. Review.
-
Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency.Nat Rev Endocrinol. 2024 Aug;20(8):487-500. doi: 10.1038/s41574-024-00985-x. Epub 2024 May 1. Nat Rev Endocrinol. 2024. PMID: 38693275 Review.
-
Approach to the Patient With Suspected Hypotonic Polyuria.J Clin Endocrinol Metab. 2025 Jan 21;110(2):e506-e514. doi: 10.1210/clinem/dgae565. J Clin Endocrinol Metab. 2025. PMID: 39148427 Free PMC article.
-
Progression from isolated growth hormone deficiency to a combined pituitary hormone deficiency in a cohort of paediatrics patients with pituitary morphology abnormalities on MRI.BMC Endocr Disord. 2025 Jul 1;25(1):157. doi: 10.1186/s12902-025-01980-7. BMC Endocr Disord. 2025. PMID: 40598088 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical